AI assistant
Beta Bionics, Inc. — Director's Dealing 2025
Jan 30, 2025
32351_dirs_2025-01-29_125c7829-49b3-4be0-b33b-e117b5867e8e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Beta Bionics, Inc. (BBNX)
CIK: 0001674632
Period of Report: 2025-01-29
Reporting Person: Hopman Mark (N/A)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Employee Stock Option (right to buy) | $5.10 | 2033-07-26 | Class B Common Stock (83242) | Direct | |
| Employee Stock Option (right to buy) | $5.10 | 2033-09-13 | Class B Common Stock (37229) | Direct | |
| Employee Stock Option (right to buy) | $8.51 | 2033-12-31 | Class B Common Stock (17765) | Direct | |
| Employee Stock Option (right to buy) | $10.74 | 2034-09-29 | Class B Common Stock (39424) | Direct |
Footnotes
F1: One-fourth of the shares subject to this option shall vest one year after March 20, 2023, and thereafter 1/36th of the shares subject to this option shall vest on each monthly anniversary thereof.
F2: In accordance with the Issuer's Amended and Restated Certificate of Incorporation, the Issuer's outstanding shares of Class B Common Stock will convert into an equal number of shares of Common Stock immediately prior to the closing of the initial public offering.
F3: The shares subject to this option shall vest in 48 equal monthly installments measured from September 14, 2023.
F4: The shares subject to this option shall vest in 48 equal monthly installments measured from January 1, 2024.
F5: The shares subject to this option shall vest in 48 equal monthly installments measured from September 10, 2024.